Prostasomes as a source of diagnostic biomarkers for prostate cancer

Journal of Clinical Investigation

Volumn 126, Issue 4, 2016, Pages 1144-1151

  Zijlstra, Carla ^a   Stoorvogel, Willem ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LONG UNTRANSLATED RNA; MESSENGER RNA; MICRORNA; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TUMOR MARKER; UNTRANSLATED RNA; PROTEASOME; RNA; TUMOR PROTEIN;

CANCER DIAGNOSIS; CANCER SCREENING; CELL LOSS; CELL POLARITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COHORT ANALYSIS; EXOSOME; FUSION GENE; GENE FUSION; HUMAN; PRIORITY JOURNAL; PROSTASOME; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; PROSTATE SECRETION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; RNA TRANSPORT; SENSITIVITY AND SPECIFICITY; URINALYSIS; ANIMAL; ENZYMOLOGY; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; BIOMARKERS, TUMOR; HUMANS; MALE; MICRORNAS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, LONG NONCODING; RNA, MESSENGER; RNA, NEOPLASM;

EID: 84964649244     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI81128     Document Type: Review

References (124)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765-781.
2. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010;46(17):3040-3052.
3. Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Rev Urol. 2008;10(2):111-119.
4. Horwich A, Parker C, de Reijke T, Kataja V, ESMO Guidelines Working Group. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi106-vi114.
5. Dijkstra S, Mulders PF, Schalken JA. Clinical use of novel urine and blood based prostate cancer biomarkers: A review. Clin Biochem. 2014;47(10-11):889-896.
6. Sartori DA, Chan DW. Biomarkers in prostate cancer: what's new? Curr Opin Oncol. 2014;26(3):259-264.
7. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8(4):268-278.
8. Barry MJ. Clinical practice. Prostate-specificantigen testing for early diagnosis of prostate cancer. N Engl J Med. 2001;344(18):1373-1377.
9. Aalberts M, Stout TA, Stoorvogel W. Prostasomes: extracellular vesicles from the prostate. Reproduction. 2013;147(1):R1-R14.
10. Andriole GL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125-132.
11. Catalona WJ. Management of cancer of the prostate. N Engl J Med. 1994;331(15):996-1004.
12. Harvey P, Basuita A, Endersby D, Curtis B, Iacovidou A, Walker M. A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol. 2009;9:14.
13. Duijvesz D, Luider T, Bangma CH, Jenster G. Exosomes as biomarker treasure chests for prostate cancer. Eur Urol. 2011;59(5):823-831.
14. Huang YQ, Sun T, Zhong WD, Wu CL. Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. Am J Clin Exp Urol. 2014;2(4):343-350.
15. Filella X, Foj L. Emerging biomarkers in the detection and prognosis of prostate cancer. Clin Chem Lab Med. 2015;53(7):963-973.
16. Thompson IM, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-2246.
17. Bussemakers MJ, et al. DD3: A new prostatespecific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59(23):5975-5979.
18. Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol. 2012;187(3):795-801.
19. Groskopf J, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52(6):1089-1095.
20. Stephan C, Ralla B, Jung K. Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochim Biophys Acta. 2014;1846(1):99-112.
21. Tomlins SA, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644-648.
22. Leyten GH, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014;65(3):534-542.
23. Laxman B, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008;68(3):645-649.
24. Stegmayr B, Ronquist G. Promotive effect on human sperm progressive motility by prostasomes. Urol Res. 1982;10(5):253-257.
25. Ronquist G. Prostasomes are mediators of intercellular communication: from basic research to clinical implications. J Intern Med. 2012;271(4):400-413.
26. Ronquist G, Brody I. The prostasome: its secretion and function in man. Biochim Biophys Acta. 1985;822(2):203-218.
27. Sahlen GE, Egevad L, Ahlander A, Norlen BJ, Ronquist G, Nilsson BO. Ultrastructure of the secretion of prostasomes from benign and malignant epithelial cells in the prostate. Prostate. 2002;53(3):192-199.
28. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373-383.
29. Carlsson L, Nilsson O, Larsson A, Stridsberg M, Sahlen G, Ronquist G. Characteristics of human prostasomes isolated from three different sources. Prostate. 2003;54(4):322-330.
30. Utleg AG, et al. Proteomic analysis of human prostasomes. Prostate. 2003;56(2):150-161.
31. Poliakov A, Spilman M, Dokland T, Amling CL, Mobley JA. Structural heterogeneity and protein composition of exosome-like vesicles (prostasomes) in human semen. Prostate. 2009;69(2):159-167.
32. Fernandez JA, Heeb MJ, Radtke KP, Griffin JH. Potent blood coagulant activity of human semen due to prostasome-bound tissue factor. Biol Reprod. 1997;56(3):757-763.
33. Arienti G, Polci A, Carlini E, Palmerini CA. Transfer of CD26/dipeptidyl peptidase IV (E.C.3.5.4.4) from prostasomes to sperm. FEBS Lett. 1997;410(2-3):343-346.
34. Yu JL, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105(4):1734-1741.
35. Muralidharan-Chari V, et al. ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol. 2009;19(22):1875-1885.
36. Di Vizio D, et al. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 2009;69(13):5601-5609.
37. Duijvesz D, et al. Immuno-based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer. Int J Cancer. 2015;137(12):2869-2878.
38. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids - The mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8(8):467-477.
39. Iero M, et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 2008;15(1):80-88.
40. Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle. 2009;8(13):2014-2018.
41. Ronquist KG, Ronquist G, Larsson A, Carlsson L. Proteomic analysis of prostate cancer metastasis-derived prostasomes. Anticancer Res. 2010;30(2):285-290.
42. Babiker AA, Magnusson PU, Ronquist G, Nilsson B, Ekdahl KN. Mapping pro-and antiangiogenic factors on the surface of prostasomes of normal and malignant cell origin. Prostate. 2010;70(8):834-847.
43. Di Vizio D, et al. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol. 2012;181(5):1573-1584.
44. Hosseini-Beheshti E, Pham S, Adomat H, Li N, Tomlinson Guns ES. Exosomes as biomarker enriched microvesicles: characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes. Mol Cell Proteomics. 2012;11(10):863-885.
45. Sahlen G, Ahlander A, Frost A, Ronquist G, Norlen BJ, Nilsson BO. Prostasomes are secreted from poorly differentiated cells of prostate cancer metastases. Prostate. 2004;61(3):291-297.
46. Nilsson BO, Egevad L, Jin M, Ronquist G, Busch C. Distribution of prostasomes in neoplastic epithelial prostate cells. Prostate. 1999;39(1):36-40.
47. Rak J, Guha A. Extracellular vesicles - vehicles that spread cancer genes. Bioessays. 2012;34(6):489-497.
48. Ekdahl KN, Ronquist G, Nilsson B, Babiker AA. Possible immunoprotective and angiogenesis-promoting roles for malignant cell-derived prostasomes: A new paradigm for prostatic cancer? Adv Exp Med Biol. 2006;586:107-119.
49. Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: A comprehensive review. Cancer Metastasis Rev. 2013;32(3-4):623-642.
50. Corcoran C, et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One. 2012;7(12):e50999.
51. Melo SA, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177-182.
52. Lee TH, D'Asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J. Microvesicles as mediators of intercellular communication in cancer - The emerging science of cellular 'debris'. Semin Immunopathol. 2011;33(5):455-467.
53. Nilsson BO, Carlsson L, Larsson A, Ronquist G. Autoantibodies to prostasomes as new markers for prostate cancer. Ups J Med Sci. 2001;106(1):43-49.
54. Minelli A, Ronquist G, Carlsson L, Mearini E, Nilsson O, Larsson A. Antiprostasome antibody titres in benign and malignant prostate disease. Anticancer Res. 2005;25(6C):4399-4402.
55. Tavoosidana G, et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc Natl Acad Sci U S A. 2011;108(21):8809-8814.
56. Øverbye A, et al. Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget. 2015;6(30):30357-30376.
57. Sandvig K, Llorente A. Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3. Mol Cell Proteomics. 2012;11(7):M111.012914.
58. Duijvesz D, et al. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PLoS One. 2013;8(12):e82589.
59. Hessvik NP, Phuyal S, Brech A, Sandvig K, Llorente A. Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim Biophys Acta. 2012;1819(11-12):1154-1163.
60. Ronquist KG, Carlsson L, Ronquist G, Nilsson S, Larsson A. Prostasome-derived proteins capable of eliciting an immune response in prostate cancer patients. Int J Cancer. 2006;119(4):847-853.
61. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev. 2000;14(19):2410-2434.
62. Larsson A, et al. Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability. Urol Oncol. 2006;24(3):195-200.
63. Stewart AB, Delves GH, Birch BR, Cooper AJ, Lwaleed BA. Antiprostasome antibodies are not an appropriate prognostic marker for prostate cancer. Scand J Urol Nephrol. 2009;43(2):104-108.
64. Khan S, et al. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One. 2012;7(10):e46737.
65. Gabriel K, et al. Regulation of the tumor suppressor PTEN through exosomes: A diagnostic potential for prostate cancer. PLoS One. 2013;8(7):e70047.
66. Kato T, et al. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer. Urol Oncol. 2015;33(9):385.e15-e20.
67. Nilsson J, et al. Prostate cancer-derived urine exosomes: A novel approach to biomarkers for prostate cancer. Br J Cancer. 2009;100(10):1603-1607.
68. Principe S, et al. In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine. Proteomics. 2013;13(10-11):1667-1671.
69. Dijkstra S, et al. Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol. 2014;191(4):1132-1138.
70. Huang X, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015;67(1):33-41.
71. Mitchell PJ, et al. Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med. 2009;7:4.
72. Lizana J, Moberg PJ, Eneroth P. β2-Microglobulin, carcinoembryonic antigen and prostatic acid phosphatase in split ejaculates and urine voided before and after massage of the prostate. Arch Androl. 1983;11(3):225-232.
73. Kim Y, et al. Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics. 2012;11(12):1870-1884.
74. Gamez-Valero A, Lozano-Ramos SI, Bancu I, Lauzurica-Valdemoros R, Borras FE. Urinary extracellular vesicles as source of biomarkers in kidney diseases. Front Immunol. 2015;6:6.
75. Perez A, et al. A pilot study on the potential of RNA-associated to urinary vesicles as a suitable non-invasive source for diagnostic purposes in bladder cancer. Cancers (Basel). 2014;6(1):179-192.
76. Wang Z, Hill S, Luther JM, Hachey DL, Schey KL. Proteomic analysis of urine exosomes by multidimensional protein identification technology (MudPIT). Proteomics. 2012;12(2):329-338.
77. Gonzales PA, et al. Isolation and purification of exosomes in urine. Methods Mol Biol. 2010;641:89-99.
78. Prunotto M, et al. Proteomic analysis of podocyte exosome-enriched fraction from normal human urine. J Proteomics. 2013;82:193-229.
79. Gonzales PA, et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol. 2009;20(2):363-379.
80. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-659.
81. Villarroya-Beltri C, Baixauli F, Gutierrez-Vazquez C, Sanchez-Madrid F, Mittelbrunn M. Sorting it out: regulation of exosome loading. Semin Cancer Biol. 2014;28:3-13.
82. Villarroya-Beltri C, et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun. 2013;4:2980.
83. Koppers-Lalic D, et al. Nontemplated nucleotide additions distinguish the small RNA composition in cells from exosomes. Cell Rep. 2014;8(6):1649-1658.
84. Bolukbasi MF, et al. miR-1289 and "Zipcode"-like sequence enrich mRNAs in microvesicles. Mol Ther Nucleic Acids. 2012;1:e10.
85. Batagov AO, Kuznetsov VA, Kurochkin IV. Identification of nucleotide patterns enriched in secreted RNAs as putative cis-acting elements targeting them to exosome nano-vesicles. BMC Genomics. 2011;12(suppl 3):S18.
86. Szostak N, et al. Sorting signal targeting mRNA into hepatic extracellular vesicles. RNA Biol. 2014;11(7):836-844.
87. Batagov AO, Kurochkin IV. Exosomes secreted by human cells transport largely mRNA fragments that are enriched in the 3'-untranslated regions. Biol Direct. 2013;8:12.
88. Hong BS, et al. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics. 2009;10:556.
89. Shao H, et al. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun. 2015;6:6999.
90. Neeb A, et al. Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer. Oncotarget. 2014;5(18):8681-8689.
91. Donovan MJ, et al. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis. 2015;18(4):370-375.
92. Jansen FH, et al. Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins. Mol Cell Proteomics. 2009;8(6):1192-1205.
93. Chen WW, et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic Acids. 2013;2:e109.
94. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.
95. Hart M, et al. Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing. Mol Cancer Res. 2014;12(2):250-263.
96. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67(13):6130-6135.
97. Lu J, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-838.
98. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857-866.
99. Hessvik NP, Sandvig K, Llorente A. Exosomal miRNAs as biomarkers for prostate cancer. Front Genet. 2013;4:36.
100. Ronnau CG, Verhaegh GW, Luna-Velez MV, Schalken JA. Noncoding RNAs as novel biomarkers in prostate cancer. Biomed Res Int. 2014;2014:591703.
101. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704-714.
102. Weber JA, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56(11):1733-1741.
103. Bryant RJ, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012;106(4):768-774.
104. Arroyo JD, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108(12):5003-5008.
105. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010;38(20):7248-7259.
106. Ouimet M, Moore KJ. A big role for small RNAs in HDL homeostasis. J Lipid Res. 2013;54(5):1161-1167.
107. Jackson BL, Grabowska A, Ratan HL. MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers. BMC Cancer. 2014;14:930.
108. Wang J, Zhang KY, Liu SM, Sen S. Tumor-associated circulating micrornas as biomarkers of cancer. Molecules. 2014;19(2):1912-1938.
109. Brase JC, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011;128(3):608-616.
110. Yaman Agaoglu F, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 2011;32(3):583-588.
111. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One. 2009;4(7):e6229.
112. Selth LA, et al. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer. 2012;131(3):652-661.
113. Chen ZH, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 2012;72(13):1443-1452.
114. Shen J, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012;72(13):1469-1477.
115. Mitchell PS, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513-10518.
116. Li M, et al. An optimized procedure for exosome isolation and analysis using serum samples: Application to cancer biomarker discovery. Methods. 2015;87:26-30.
117. Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer. 2014;5(3):182-191.
118. Srivastava A, et al. MicroRNA profiling in prostate cancer - The diagnostic potential of urinary miR-205 and miR-214. PLoS One. 2013;8(10):e76994.
119. Cheng L, Sun X, Scicluna BJ, Coleman BM, Hill AF. Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine. Kidney Int. 2014;86(2):433-444.
120. Tolle A, Ratert N, Jung K. miRNA panels as biomarkers for bladder cancer. Biomark Med. 2014;8(5):733-746.
121. Hanke M, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol. 2010;28(6):655-661.
122. Korzeniewski N, Tosev G, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S. Identification of cell-free microRNAs in the urine of patients with prostate cancer. Urol Oncol. 2015;33(1):16.
123. Mizutani K, et al. Isolation of prostate cancer-related exosomes. Anticancer Res. 2014;34(7):3419-3423.
124. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426-437.